Stephen Chan

Active 1987–2026

132
Papers
19,358
Citations
76
h-index
111
i10-index

Citations

Citations per year for Stephen Chan1971: 1 citations1989: 1 citations1991: 1 citations1992: 2 citations1993: 4 citations1994: 2 citations1995: 2 citations1997: 1 citations1998: 2 citations1999: 8 citations2000: 22 citations2001: 35 citations2002: 43 citations2003: 43 citations2004: 63 citations2005: 85 citations2006: 105 citations2007: 131 citations2008: 178 citations2009: 175 citations2010: 192 citations2011: 146 citations2012: 171 citations2013: 141 citations2014: 188 citations2015: 161 citations2016: 150 citations2017: 164 citations2018: 170 citations2019: 457 citations2020: 560 citations2021: 581 citations2022: 399 citations2023: 328 citations2024: 453 citations2025: 195 citations2026: 13 citations1972–1988: no citations, so these years are not shown1990: no citations, so this year is not shown1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,000 citing papers, 24.2% of this breakdownChina: 749 citing papers, 9.1% of this breakdownUnited Kingdom: 617 citing papers, 7.5% of this breakdownItaly: 427 citing papers, 5.2% of this breakdownGermany: 360 citing papers, 4.3% of this breakdownFrance: 352 citing papers, 4.3% of this breakdownCanada: 297 citing papers, 3.6% of this breakdownSpain: 279 citing papers, 3.4% of this breakdownAustralia: 232 citing papers, 2.8% of this breakdownJapan: 198 citing papers, 2.4% of this breakdownSwitzerland: 188 citing papers, 2.3% of this breakdownIndia: 184 citing papers, 2.2% of this breakdown
0%24.2%Other 28.7%

Fields

  • Medicine55.4%
  • Biochemistry, Genetics and Molecular Biology25.2%
  • Computer Science4.6%
  • Environmental Science2.2%
  • Materials Science2.1%
  • Immunology and Microbiology2%
  • Other8.5%

Topics

  • HER2/EGFR in Cancer Research6.3%
  • Cancer Treatment and Pharmacology4.1%
  • Breast Cancer Treatment Studies3.7%
  • Advanced Breast Cancer Therapies3.2%
  • PI3K/AKT/mTOR signaling in cancer2.3%
  • PARP inhibition in cancer therapy2%
  • Other78.4%

Coauthors

All papers

Open in search
  1. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 389

  2. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2006 cited by 3,461

  3. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2020 cited by 262

  4. Towards Automated Annotation of Benthic Survey Images: Variability of Human Experts and Operational Modes of Automation

    Authors: , , , , , , , , , , , , , , - PLoS ONE 2015 cited by 381

  5. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2011 cited by 1,061

  6. Representativeness of Eddy-Covariance flux footprints for areas surrounding AmeriFlux sites

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Timothy J. Griffis, Manuel Helbig, David Y. Hollinger, Elyn Humphreys, Hiroki Ikawa, Hiroki Iwata, Yang Ju, John F. Knowles, Sara Knox, Hideki Kobayashi, Thomas E. Kolb, B. E. Law, Xuhui Lee, M. E. Litvak, Heping Liu, J. William Munger, Asko Noormets, Kim Novick, Steven F. Oberbauer, Walter C. Oechel, Patty Oikawa, S. A. Papuga, Elise Pendall, Prajaya Prajapati, John H. Prueger, William L. Quinton, Andrew D. Richardson, Eric S. Russell, Russell L. Scott, Gregory Starr, Ralf M. Staebler, Paul C. Stoy, Ellen Stuart‐Haëntjens, Oliver Sonnentag, Ryan C. Sullivan, Andy Suyker, Masahito Ueyama, Rodrigo Vargas, Jeffrey D. Wood, Donatella Zona - Agricultural and Forest Meteorology 2021 cited by 504

  7. A New Deep Learning Engine for CoralNet

    Authors: , , , , - IEEE/CVF International Conference on Computer Vision Workshops (ICCVW) 2021 cited by 76

  8. Discovery and Structure–Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening

    Authors: , , , , , , , - Journal of Medicinal Chemistry 2016 cited by 146

  9. GARCH Modelling of Cryptocurrencies

    Authors: , , , - Journal of risk and financial management 2017 cited by 344

  10. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - Molecular Oncology 2014 cited by 149

  11. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kelly Mousa, Javier Cortés - JAMA Oncology 2019 cited by 90

  12. Multimodal human attention detection for reading from facial expression, eye gaze, and mouse dynamics

    Authors: , , , - ACM SIGAPP Applied Computing Review 2016 cited by 51

  13. Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer

    Authors: , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2014 cited by 210

  14. The adaptive market hypothesis in the high frequency cryptocurrency market

    Authors: , , - International Review of Financial Analysis 2019 cited by 138

  15. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 251

  16. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Doris Augustin, Heiko Graf, Georg Heinrich, Hendrik Kroening, Sherko Küemmel, Volkmar Müller, Friedrich Overkamp, Tjoung‐Won Park‐Simon, Marcus Schmidt, Lidia Perlova-Griff, Christopher Wolf, Marco Colleoni, Alberto Ballestrero, Antônio Bernardo, Angela Stefania Ribecco, Luca Gianni, Giuseppe Curigliano, E. Brewczynska, Jacek Jassem, Vadim Shirinkin, Alexey Manikhas, В. В. Дворниченко, Mikhail Lichinitser, Semiglazov Vf, Guzel Mukhametshina, Irina Bulavina, Enrique Espinosa Arranz, Francisco Carabantes Ocón, Guillermo López-Vivanco, Javier Salvador Bofill, Ignacio Porras Quintela, Alfonso Sánchez Muñoz, Yolanda Fernández Pérez, Javier Cassinello Espinosa, Jose Alvarez, Rodrigo Lastra del Prado, LuisLa Cruz De Merino, José Manuel Pérez García, Santos Enrech Francés, Per Edlund, Bengt Norberg, Anna-Karin Wennstig, Pehr Lind, Nik Hauser, Christoph Tausch, Celalettin Camcı, Fikret Arpacı, Hüseyin Abalı, Rüçhan Uslu, Saad Tahir, Duncan Wheatley, Stephen Chan, Peter Barrett‐Lee, Karen McAdam, Richard Simcock, Russell Burcombe, Robert H. El-Maraghi, Nadia Califaretti, Silvana Spadafora, Sandeep Sehdev, Amer Sami, Sunil Verma - Annals of Oncology 2014 cited by 176

  17. Development of Decellularized Human Umbilical Arteries as Small-Diameter Vascular Grafts

    Authors: , , , , - Tissue Engineering Part A 2009 cited by 248

  18. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

    Authors: , , , , , , , , , , , , - Annals of Oncology 2016 cited by 114

  19. Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer

    Authors: , , , , , , , , - Clinical Cancer Research 2013 cited by 108

  20. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Breast Cancer Research and Treatment 2008 cited by 803

  21. Hippocampal sclerosis after febrile status epilepticus: The FEBSTAT study

    Authors: , , , , , , , , , , , , , , , , , , , , - Annals of Neurology 2013 cited by 282

  22. AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2013 cited by 257

  23. MRI abnormalities following febrile status epilepticus in children

    Authors: , , , , , , , , , , , , - Neurology 2012 cited by 212

  24. Bitcoin versus high-performance technology stocks in diversifying against global stock market indices

    Authors: , , - Physica A Statistical Mechanics and its Applications 2021 cited by 32